For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

CJC-1295 / Ipamorelin Stack vs Mod-GRF(1-29)

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

CJC-1295 / Ipamorelin StackMod-GRF(1-29)
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asCJC-1295 Ipamorelin, Mod GRF 1-29 Ipamorelin, CJC Ipa stack, CJC-1295 without DAC with Ipamorelin, GHRH GHRP combinationModified GRF(1-29), CJC-1295 without DAC, Tetrasubstituted GRF, Sermorelin analog
EvidenceFDA-approvedResearch-stage
Dosing range100mcg each–300mcg each mcg, once daily before sleep (or 2–3x daily for more aggressive protocols)100mcg–200mcg mcg, 2–3x daily, co-administered with a GHRP (pre-sleep, pre-workout, and/or upon waking)
AdministrationSubcutaneous injection (both compounds), Administered together in the same injectionSubcutaneous injection, Intramuscular injection
Key side effectsWater retention (mild, common), Tingling or numbness in hands/feet (transient), Headache (usually first 1–2 weeks), Fatigue or increased sleepiness (often desired at night dose)Water retention (mild, dose-dependent), Tingling / numbness in extremities (carpal tunnel-like at high doses), Increased appetite (via GHRP component — less with Mod-GRF alone), Flushing or warmth at injection site
Cited sources2 references2 references

Key differences

  • Evidence level differs: CJC-1295 / Ipamorelin Stack is fda-approved, while Mod-GRF(1-29) is research-stage.
  • Administration: CJC-1295 / Ipamorelin Stack — Subcutaneous injection (both compounds), Administered together in the same injection; Mod-GRF(1-29) — Subcutaneous injection, Intramuscular injection.
  • Frequency: CJC-1295 / Ipamorelin Stack is typically once daily before sleep (or 2–3x daily for more aggressive protocols); Mod-GRF(1-29) is 2–3x daily, co-administered with a GHRP (pre-sleep, pre-workout, and/or upon waking).

How each works

CJC-1295 / Ipamorelin Stack

CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on the pituitary, increasing the amplitude of GH pulses. Ipamorelin independently triggers GH release via the ghrelin receptor (GHS-R1a) with high selectivity — minimal cortisol, prolactin, or aldosterone co-elevation. The combination exploits two separate receptor pathways to produce synergistic GH output. Animal and human studies on each compound individually confirm GH and IGF-1 elevation. The combination is extrapolated from mechanistic research and is the most studied protocol in the peptide research community.

Mod-GRF(1-29)

Native GHRH(1-29) is rapidly cleaved by plasma dipeptidyl peptidase IV (DPP-IV) within 2–3 minutes. Mod-GRF(1-29) incorporates four amino acid substitutions (positions 2, 8, 15, 27) that resist DPP-IV degradation, extending the half-life to approximately 30 minutes while preserving GHRH receptor binding affinity. This creates a half-life window aligned with physiological GH pulsatility, making it suitable for 2–3x daily injections that mimic natural GH release patterns.

Read the full CJC-1295 / Ipamorelin Stack profileRead the full Mod-GRF(1-29) profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.